April 23, 2018 9:23 PM ET

Pharmaceuticals

Company Overview of Claris Lifesciences Limited

Company Overview

Claris Lifesciences Limited, together with its subsidiaries, engages in the manufacture and wholesale of drugs and pharmaceuticals worldwide. The company manufactures and markets products for anesthesia and analgesics, blood, anti-infectives, plasma volume expanders, critical care, and nephrology areas, as well as for infusion therapy and nutrition applications. It also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. The company offers its products through various delivery systems, such as glass and plastic bottles, ampoules, and non-PVC/PVC bags. It primarily serves government and private hospitals, aid agencies, and nursing homes. Th...

Near Parimal Railway Crossing

Ellisbridge

Ahmedabad,  380006

India

Founded in 1994

1,640 Employees

Phone:

91 79 2656 3331

Fax:

91 79 2640 8053

Key Executives for Claris Lifesciences Limited

Vice Chairman & MD
Age: 37
Founder and Co-Promoter
CFO & Whole Time Director
Age: 43
President of Corporate Planning & Strategy
SVP, Compliance Officer & Company Secretary
Compensation as of Fiscal Year 2017.

Claris Lifesciences Limited Key Developments

Claris Lifesciences Limited To Be Delisted From The BSE From March 22

Shares of Claris Lifesciences will be delisted from the BSE from March 22 and added that trading in the shares will be stopped from March 15. Shares of the company are not traded on the NSE. “Pursuant to the final delisting approval, the ‘permitted to trade’ status given to the equity shares by the Metropolitan Stock Exchange of India shall also stand withdrawn on and from the date of discontinuation of trading,”. The company had applied for delisting of the equity shares from the exchange on February 26. The promoter/promoter group of the company had made a voluntary delisting offer representing 49.87% of the paid-up share capital of the company held by public shareholders.

Claris Lifesciences Limited Announces Letter Of Offer By Acquirers With Respect To Voluntary Delisting From BSE

Claris Lifesciences Limited announced that letter of offer made by Athanas Enterprise Private Limited ('AEPL' or the 'Promoter') and Claris Holdings Private Limited ('CHPL') (collectively referred to as 'Acquirers') with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provision of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 as amended from time to time ('SEBI Delisting Regulations').

Claris Lifesciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017

Claris Lifesciences Limited reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, on standalone basis, the company reported total income of INR 572.240 million against INR 128.545 million for the same period previous year. Profit before share of profit of associates, exceptional items and tax from continuing operations was INR 410.636 million against loss of INR 99.826 million for the same period of previous year. Profit before tax from continuing operations was INR 410.636 million against loss of INR 99.826 million for the same period of previous year. Net loss was INR 3,201.617 million or INR 58.67 per basic and diluted share compared to profit of INR 83.012 million or INR 1.52 per diluted share for the same period of previous year. For the nine months, on standalone basis, the company reported total income of INR 1,154.309 million against INR 548.619 million for the same period previous year. Profit before share of profit of associates, exceptional items and tax from continuing operations was INR 672.529 million against loss of INR 75.746 million for the same period of previous year. Profit before tax from continuing operations was INR 672.529 million against loss of INR 75.746 million for the same period of previous year. Net profit was INR 13,735.517 million or INR 251.71 per basic and diluted share compared to INR 172.970 million or INR 3.16 per diluted share for the same period of previous year. For the quarter, on consolidated basis, the company reported total income of INR 614.846 million against INR 55.282 million for the same period previous year. Profit before share of profit of associates, exceptional items and tax from continuing operations was INR 444.825 million against loss of INR 182.716 million for the same period of previous year. Profit before tax from continuing operations was INR 444.825 million against loss of INR 347.708 million for the same period of previous year. Net loss was INR 3,174.298 million or INR 58.17 per basic and diluted share compared to profit of INR 185.749 million or INR 3.40 per diluted share for the same period of previous year. For the nine months, on standalone basis, the company reported total income of INR 1,225.812 million against INR 358.373 million for the same period previous year. Profit before share of profit of associates, exceptional items and tax from continuing operations was INR 654.008 million against loss of INR 290.559 million for the same period of previous year. Profit before tax from continuing operations was INR 637.762 million against loss of INR 515.726 million for the same period of previous year. Net profit was INR 15,420.522 million or INR 282.59 per basic and diluted share compared to INR 729.607 million or INR 13.37 per diluted share for the same period of previous year.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 2, 2017
--
Merger/Acquisition
May 8, 2017
Otsuka Pharmaceutical India Private Limited
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Claris Lifesciences Limited, please visit www.clarislifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.